CBD Continues to Thrive in Both Recreational and Medical Cannabis Markets
FinancialBuzz.com News Commentary
News provided by
Mar 27, 2019, 09:00 ET
Share this article
Share this article
NEW YORK , March 27, 2019 /PRNewswire/ — Cannabis is a family of plants with two primary classifications, Indica and Sativa. Despite the two falling under one cannabis family, they are widely different in their biological makeup and effects. Although marijuana can fall into either family, marijuana is linked to having psychoactive effects on the user because of its tetrahydrocannabinol or THC component-heavy makeup. On the other hand, hemp does not provide psychoactive effects because of its main component, cannabidiol or CBD and while marijuana can contain anywhere from 15% to 40% of THC concentration, hemp normally contains less than 0.3%. In fact, it is the heavy THC concentration within marijuana which caused international organizations to put restrictions on the plant, making it one of the most enforced drugs worldwide. However, due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant. In particular, most countries are looking to adopt a cannabis legislation for medical applications, but countries like the U.S. and Canada have already established a large recreational user base. Overall, the combination of the accelerating recreational and medical sectors is set to caus the greater cannabis industry to witness sizeable growth in the near future. According to data compiled by Grand View Research, the global legal marijuana market is expected to reach USD 146.4 Billion by 2025, exhibiting a CAGR of 34.6%. Chineseinvestors.com Inc. (OTC: CIIX), Aphria Inc. (NYSE: APHA) (TSX: APHA), New Age Beverages Corporation (NASDAQ: NBEV), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), The Alkaline Water Company Inc. (NASDAQ: WTER) (TSX-V: WTER).
The medical market accounts for the largest share of the overall cannabis industry, but the U.S. and Canada are expected to gradually shift the market from medical to recreational. Currently, the recreational market has a very limited geographic reach due to legality matters, when compared to the medical sector. While the two markets are perceived very differently, one cannabis-based product is still thriving in both: CBD. In the recreational sector, consumers are using CBD products to simply relax, while medically, consumers are using it to treat sleep disorders and depression. Specifically, within the CBD marketplace, CBD hemp oil accounts for the largest share of the market because of its healthcare associated benefits. According to data compiled by Transparency Market Research, the global CBD hemp oil market was valued at USD 950 Million in 2017 and is expected to surpass USD 2.5 Billion by 2026. Additionally, the market is also expected to register a CAGR of 11% from 2018 to 2026. CBD oil is mainly being used for medical applications, but the increasing usage of oil in forms of spray, vape, and tinctures is expected to propel the entire industry. “It actually doesn’t produce any psychoactive effects, that’s why it’s actually legal and people don’t have to worry about abusing it or passing a drug test, or having any type of side effects,” said Alleyah Miner of AltPharm in Camp Springs. “I think it’s great to be us and bring it to the market because cbd has a lot of health benefits anti-inflammation for depression for stress pain relief.”
Chineseinvestors.com Inc. (OTCQB: CIIX) earlier this week announced breaking news that, “it will add a high-end, luxury brand of full spectrum CBD oil to its product offerings.
ChineseHempOil.com, Inc.’s new product was launched on March 9, 2019 , at San Francisco’s KTSF-hosted Financial Carnival Event. The launch has proven successful, with sales exceeding $10,000 on the first day. Based on the initial reception and the price point for this top of the line CBD oil, the Company expects that this new addition should have a positive impact on revenues and should increase margins.
“Since the beginning of 2019, ChineseInvestors.com, Inc., and its wholly owned subsidiary ChineseHempOil.com, Inc., have been on the lookout for innovative CBD products for the global Chinese market,” stated Warren Wang , Chief Executive Officer of ChineseInvestors.com. “This 100% organic product, free of pesticides, herbicides, and chemical fertilizers, will provide our most discerning, health conscious customers with one of the highest quality CBD oils available.”
Products are available for purchase on the Company’s new platform, www.365cwc.com, which caters to both Chinese and English-speakers and offers a wide selection of wellness products, including:
OPT Hemp: Products include organic industrial hemp-derived CBD oil, CBD scrub and cream, with additional hemp-infused cosmetics and other industrial hemp-derived CBD products in the works.
OPT2Mist: A ground-breaking nutritional spray product line including a wide array of daily vitamin sprays, and full-spectrum CBD-infused sprays.
Our latest organic full spectrum CBD oil: A high-grade, organic, full spectrum hemp oil sourced from Colorado and free of pesticides, herbicides, and chemical fertilizers.
Dedicated to spreading awareness about the benefits of CBD, ChineseHempOil.com has been operating in the United States since 2017. Equipped with its strong reputation and its popular product lines, ChineseHempOil.com is constantly developing new and innovative ways to promote wellness in the Chinese community.
For more information, please visit www.365cwc.com.
About ChineseInvestors.com – Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information, visit ChineseInvestors.com.
Aphria Inc. (NYSE: APHA) (TSX: APHA) is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Aphria Inc. and Rapid Dose Therapeutics Inc. (CSE: DOSE) recently announced that they have expanded the scope of their previously announced agreement expanding the territory where Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT’s QuickStrip™ innovative, proprietary delivery technology for the cannabis market to Germany . RDT’s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers. Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Spring 2019. As part of the Agreement, Aphria maintains the option to add future international markets as the opportunity in those markets evolve. ” Germany is one of the most sought-after cannabis markets today, and Aphria continues to take a comprehensive approach to ensure a leading presence in the country as the opportunity evolves,” said Jakob Ripshtein, President of Aphria. “Aphria is committed to bringing advanced products and innovations to cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip™ technology to the German market and offer a unique nutraceutical product that delivers a consistent dosage.”
New Age Beverages Corporation (NASDAQ: NBEV) is a Colorado and Utah -based healthy beverage company dedicated to inspiring, educating consumers to live healthily. New Age Beverages Corporation recently announced the signing of an agreement to develop and distribute Marley branded cannabis-infused beverages. The first product to rollout in the Marley+CBD portfolio will be Marley+CBD Mellow Mood, relaxation drinks in 15.5 oz cans with 25 mg of pharmaceutical grade CBD per serving. Initial market rollout to customers will be in Colorado , Oregon , Washington , and Michigan where cannabis is legal for responsible adult consumption. This rollout gives New Age a significant first-mover advantage in the CBD space with a globally-recognized brand platform, and positions the venture well for further expansion as regulations permit. Michael Cunningham , Senior Vice President of Sales for New Age commented, “It makes my job a lot easier when I have retailers and distributors reaching out to me asking for specific products. From the moment the CBD movement began, I’ve been receiving calls nonstop asking when we’d be going to market with a Marley+CBD product. Retailers and distributors realize that it will be a long road for smaller CBD brands to gain traction and brand equity. Under the Marley brand platform, we are able to leverage a massive global brand with ties to healthy cannabis use, to ultimately grow a beverage brand beyond anything we have seen to-date.”
/PRNewswire/ — Cannabis is a family of plants with two primary classifications, Indica and Sativa. Despite the two falling under one cannabis family, they are…
Does CBD Really Do Anything?
PHOTO ILLUSTRATION BY FIVETHIRTYEIGHT / GETTY IMAGES
As marijuana is legalized in more and more states, the wellness world has whipped itself into a frenzy over a non-intoxicating cannabis derivative called cannabidiol. CBD products can be found on the internet and in health-food stores, wellness catalogs and even bookstores. (A bookstore in downtown Boulder, Colorado, displays a case of CBD products between the cash register and the stacks of new releases.) Celebrities like Gwyneth Paltrow, disgraced cyclist
‘> 1 Floyd Landis and former Denver Broncos quarterback Jake Plummer are all touting CBD products, and according to Bon Appétit, CBD-infused lattes have become “the wellness world’s new favorite drink.”
But, uh, what is it that CBD is supposed to do? I visited a cannabis dispensary in Boulder to find out what the hype was all about. After passing an ID check, I was introduced to a “budtender” who pointed me to an impressive array of CBD products — tinctures, skin patches, drink powders, candies, salves, massage oil, lotions, “sexy time personal intimacy oil” and even vaginal suppositories to treat menstrual cramps.
Most of these products promised to relieve pain or otherwise enhance well-being, and none of it was cheap. (Prices started at about $30.) But I wanted to know: Does any of this stuff really work? After a deep dive into the scientific research, I learned that the answer was a big fat maybe.
Although there’s enticing evidence that good ol’ cannabis can ease chronic pain and possibly treat some medical conditions, whether CBD alone can deliver the same benefits remains an open question. What is clear, at this point, is that the marketing has gotten way ahead of the science.
Cannabinoids are a class of compounds that interact with receptors throughout your body. CBD is just one of dozens of cannabinoids found in cannabis, including tetrahydrocannabinol (THC), which is the one responsible for marijuana’s famous high. Medical cannabis is technically any cannabis product used for medicinal purposes, and these can contain THC or CBD or both, said Nick Jikomes, a neuroscientist at Leafly, a website that provides information about legal cannabis. “A common mistake people make is to think that CBD is ‘the medical cannabinoid’ and THC is ‘the recreational cannabinoid.’” That’s inaccurate, he said, because THC is a potent anti-inflammatory and can be helpful for pain.
What makes CBD so appealing is that it’s non-intoxicating, so it won’t get you high, though it “is technically psychoactive, because it can influence things like anxiety,” Jikomes said. Although much of the marketing blitz around CBD centers on the fact that you can take it without getting stoned, there isn’t much research looking at the effects of CBD when used in isolation, with a couple of exceptions. One is the use of CBD to treat seizures: CBD is the active ingredient in the only cannabis product that the Food and Drug Administration has signed off on — a drug called Epidiolex, which is approved for treating two rare forms of epilepsy. Animal models and a few human studies suggest that CBD can help with anxiety, but those are the only conditions with much research on CBD in isolation.
Last year, the National Academies of Sciences, Engineering and Medicine released a nearly 500-page report on the health effects of cannabis and cannabinoids. A committee of 16 experts from a variety of scientific and medical fields analyzed the available evidence — more than 10,000 scientific abstracts in all. Because so few studies examine the effects of CBD on its own, the panel did not issue any findings about CBD specifically, but it did reach some conclusions about cannabis and cannabinoids more generally. The researchers determined that there is “conclusive or substantial evidence” supporting the use of cannabis or cannabinoids for chronic pain in adults, multiple sclerosis-related spasticity (a kind of stiffness and muscle spasms), and chemotherapy-induced nausea and vomiting. The committee also found “moderate” evidence that cannabis or cannabinoids can reduce sleep disturbances in people with obstructive sleep apnea, fibromyalgia, chronic pain and multiple sclerosis, as well as “limited” evidence that these substances can improve symptoms of Tourette’s syndrome, increase appetite and stem weight loss in people with HIV/AIDs, and improve symptoms of PTSD and anxiety.
Donald Abrams was a member of the committee that reviewed the evidence that went into producing the report, and he said that the studies they reviewed overwhelmingly used pharmaceutically available preparations that contain THC, including dronabinol, nabilone and the whole-plant extract spray nabiximols, which contains equal parts CBD and THC. It’s impossible to know whether the benefits of cannabis can also be obtained from CBD alone, Abrams said, because CBD is just one of 400 chemicals present in the plant. So far, CBD in isolation has been studied in only a handful of randomized, placebo-controlled trials (considered the gold standard of evidence in medical research), and the evidence remains sparse.
Still, as the saying goes, absence of evidence isn’t necessarily evidence of absence, and there’s a reason we don’t have a ton of solid research on CBDs yet — “to study it, we need a good source, ” said Ziva Cooper, who is an associate professor at Columbia University and was on the National Academies committee. CBD is hard to get because it’s still technically a Schedule I drug, which limits its availability, Cooper said.
Cooper recently got funding from the National Institutes of Health for a study looking at cannabinoids — including CBD in isolation — as a substitute for opioids, and numerous other clinical trials of CBD are underway. It will be several years before results are available, but these studies should help clarify both what benefits the substance may provide and any side effects it may come with. Most of the adverse effects so far associated with cannabis, such as impairments in short-term memory, coordination and judgment,
Also known as being stoned.
“> 2 come from products that contain THC as well as CBD, Cooper said, but we need to do more studies to find out for sure whether CBD has fewer risks. Studies are also needed to identify the best way to administer and dose CBD. “I get emails from people asking me what dose of CBD to use, and the truth is, we really don’t know,” Cooper said.
In the meantime, some physicians are forging ahead — and cashing in. Joe Cohen is a doctor at Holos Health, a medical marijuana clinic in Boulder. I asked him what CBD is good for, and he read me a long list of conditions: pain, inflammation, nausea, vomiting, intestinal cramping, anxiety, psychosis, muscle spasms, hyperactive immune systems, nervous system degeneration, elevated blood sugar and more. He also claimed that CBD has anti-cancer properties and can regenerate brain cells and reduce the brain’s levels of amyloid beta — a kind of protein that’s been linked to Alzheimer’s disease. I asked for references, noting that most of these weren’t listed in the Academies report or a similar review published in the Journal of the American Medical Association. “I think you just have to Google search it,” he said. It’s true that a preliminary study found hints that cannabinoids might reduce beta amyloid proteins in human brain cells, but the study was done in cells grown in a lab, not in people. As for cancer, the FDA sent warning letters last year to four companies that were selling products that claimed to “prevent, diagnose, treat or cure” cancer.
Those warning letters aside, there’s not a lot of federal oversight right now over the claims being made or the products that are being sold. Cohen warned against buying CBD products online, because “there’s a lot of scams out there.” Yet his clinic sells CBD, and he admits, “I say ‘Don’t buy online,’ but ours is worth doing, because we know what we’re doing. We ship all over.”
Right now, there’s a good chance that you don’t really know what you’re getting from any source. Testing and labeling rules vary by state, but many states that allow legal cannabis also require some kind of testing to verify that the THC and CBD levels listed on the label are accurate. However, this testing is controversial, and results can vary widely between labs, Jikomes said. A study published in March found measurable variations in test results, with some labs consistently reporting higher or lower levels of cannabinoids than others. There are no guarantees that the label accurately reflects what’s in the product. For a 2015 study published in JAMA, researchers tested 75 products purchased in San Francisco, Los Angeles and Seattle and found that only 17 percent were accurately labeled. More than half of the products contained significantly lower levels of cannabinoids than the label promised, and some of them contained only negligible amounts of the compounds. “We need to come up with ways to confidently verify the composition of cannabis products and make this information available to consumers,” Jikomes said.
“All these people are making claims,” Abrams said, but right now, there’s little verification. “It’s the Wild West.”
As marijuana is legalized in more and more states, the wellness world has whipped itself into a frenzy over a non-intoxicating cannabis derivative called cannab…